{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:17:22Z","timestamp":1790097442215,"version":"4.0.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T00:00:00Z","timestamp":1508112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00223-017-0319-7","type":"journal-article","created":{"date-parts":[[2017,10,16]],"date-time":"2017-10-16T08:36:04Z","timestamp":1508142964000},"page":"641-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Etelcalcetide, A Novel Calcimimetic, Prevents Vascular Calcification in A Rat Model of Renal Insufficiency with Secondary Hyperparathyroidism"],"prefix":"10.1007","volume":"101","author":[{"given":"Longchuan","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn T.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Hensley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ya","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Stolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Charles","family":"Dean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,16]]},"reference":[{"key":"319_CR1","doi-asserted-by":"publisher","first-page":"F891","DOI":"10.1152\/ajprenal.00163.2014","volume":"307","author":"NJ Paloian","year":"2014","unstructured":"Paloian NJ, Giachelli CM (2014) A current understanding of vascular calcification in CKD. Am J Physiol Renal Physiol 307:F891\u2013F900","journal-title":"Am J Physiol Renal Physiol"},{"key":"319_CR2","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1681\/ASN.2011121191","volume":"24","author":"R Shroff","year":"2013","unstructured":"Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24:179\u2013189","journal-title":"J Am Soc Nephrol"},{"key":"319_CR3","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J, Advance Study Group (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327\u20131339","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR4","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/ndt\/gfs356","volume":"28","author":"PA Urena-Torres","year":"2013","unstructured":"Urena-Torres PA, Floege J, Hawley CM, Pedagogos E, Goodman WG, Petavy F, Reiner M, Raggi P (2013) Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study. Nephrol Dial Transplant 28:146\u2013152","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, Drueke TB, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Stolina M, Dehmel B, Goodman WG, Floege J, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events Trial Investigators (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial. Circulation 132:27\u201339","journal-title":"Circulation"},{"key":"319_CR6","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/ki.1990.293","volume":"38","author":"DS Milliner","year":"1990","unstructured":"Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931\u2013936","journal-title":"Kidney Int"},{"key":"319_CR7","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1093\/ndt\/gfl098","volume":"21","author":"S Briese","year":"2006","unstructured":"Briese S, Wiesner S, Will JC, Lembcke A, Opgen-Rhein B, Nissel R, Wernecke KD, Andreae J, Haffner D, Querfeld U (2006) Arterial and cardiac disease in young adults with childhood-onset end-stage renal disease-impact of calcium and vitamin D therapy. Nephrol Dial Transplant 21:1906\u20131914","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR8","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1093\/ndt\/gfr668","volume":"27","author":"D Hansen","year":"2012","unstructured":"Hansen D, Rasmussen K, Pedersen SM, Rasmussen LM, Brandi L (2012) Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrol Dial Transplant 27:2263\u20132269","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2215\/CJN.03270314","volume":"10","author":"SM Sprague","year":"2015","unstructured":"Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K (2015) Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol 10:1021\u20131030","journal-title":"Clin J Am Soc Nephrol"},{"key":"319_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.2215\/CJN.07050714","volume":"10","author":"JB Wetmore","year":"2015","unstructured":"Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K (2015) A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 10:1031\u20131040","journal-title":"Clin J Am Soc Nephrol"},{"key":"319_CR11","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/ki.2008.407","volume":"74","author":"T Kawata","year":"2008","unstructured":"Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M (2008) Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kidney Int 74:1270\u20131277","journal-title":"Kidney Int"},{"key":"319_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00223-012-9635-0","volume":"91","author":"TM Schutter De","year":"2012","unstructured":"De Schutter TM, Behets GJ, Jung S, Neven E, D\u2019Haese PC, Querfeld U (2012) Restoration of bone mineralization by cinacalcet is associated with a significant reduction in calcitriol-induced vascular calcification in uremic rats. Calcif Tissue Int 91:307\u2013315","journal-title":"Calcif Tissue Int"},{"key":"319_CR13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1681\/ASN.2005040342","volume":"17","author":"I Lopez","year":"2006","unstructured":"Lopez I, Aguilera-Tejero E, Mendoza FJ, Almaden Y, Perez J, Martin D, Rodriguez M (2006) Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J Am Soc Nephrol 17:795\u2013804","journal-title":"J Am Soc Nephrol"},{"key":"319_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/ki.2008.490","volume":"75","author":"N Koleganova","year":"2009","unstructured":"Koleganova N, Piecha G, Ritz E, Schmitt CP, Gross ML (2009) A calcimimetic (R-568), but not calcitriol, prevents vascular remodeling in uremia. Kidney Int 75:60\u201371","journal-title":"Kidney Int"},{"key":"319_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1124\/jpet.106.101261","volume":"318","author":"JR Wu-Wong","year":"2006","unstructured":"Wu-Wong JR, Noonan W, Ma J, Dixon D, Nakane M, Bolin AL, Koch KA, Postl S, Morgan SJ, Reinhart GA (2006) Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J Pharmacol Exp Ther 318:90\u201398","journal-title":"J Pharmacol Exp Ther"},{"key":"319_CR16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/sj.ki.5002406","volume":"72","author":"M Mizobuchi","year":"2007","unstructured":"Mizobuchi M, Finch JL, Martin DR, Slatopolsky E (2007) Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72:709\u2013715","journal-title":"Kidney Int"},{"key":"319_CR17","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1093\/ndt\/gfn375","volume":"23","author":"W Noonan","year":"2008","unstructured":"Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G (2008) Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 23:3824\u20133830","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR18","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.070305","volume":"22","author":"A Cardus","year":"2007","unstructured":"Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM (2007) Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22:860\u2013866","journal-title":"J Bone Miner Res"},{"key":"319_CR19","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/sj.ki.5002675","volume":"73","author":"I Lopez","year":"2008","unstructured":"Lopez I, Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F, Martin D, Rodriguez M (2008) The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 73:300\u2013307","journal-title":"Kidney Int"},{"key":"319_CR20","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1681\/ASN.2007080902","volume":"19","author":"S Mathew","year":"2008","unstructured":"Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA (2008) Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19:1509\u20131519","journal-title":"J Am Soc Nephrol"},{"key":"319_CR21","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/ki.2012.322","volume":"82","author":"WL Lau","year":"2012","unstructured":"Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, Giachelli CM (2012) Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int 82:1261\u20131270","journal-title":"Kidney Int"},{"key":"319_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1124\/jpet.113.204834","volume":"346","author":"S Walter","year":"2013","unstructured":"Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Mendel DB, Johnson RM, Karim F (2013) Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther 346:229\u2013240","journal-title":"J Pharmacol Exp Ther"},{"key":"319_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1471-2369-15-81","volume":"15","author":"S Walter","year":"2014","unstructured":"Walter S, Baruch A, Alexander ST, Janes J, Sho E, Dong J, Yin Q, Maclean D, Mendel DB, Karim F, Johnson RM (2014) Comparison of AMG 416 and cinacalcet in rodent models of uremia. BMC Nephrol 15:81","journal-title":"BMC Nephrol"},{"key":"319_CR24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/ki.2013.289","volume":"85","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, Power DA, Bell G (2014) AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int 85:191\u2013197","journal-title":"Kidney Int"},{"key":"319_CR25","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1185\/03007995.2015.1031731","volume":"31","author":"G Bell","year":"2015","unstructured":"Bell G, Huang S, Martin KJ, Block GA (2015) A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin 31:943\u2013952","journal-title":"Curr Med Res Opin"},{"key":"319_CR26","doi-asserted-by":"crossref","unstructured":"National Research Council (US) (2011) Committee for the update of the guide for the care and use of laboratory animals. Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US). \n                    http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK54050\/\n                    \n                   doi: 10.17226\/12910","DOI":"10.17226\/12910"},{"key":"319_CR27","first-page":"257","volume":"4","author":"SB Nicholas","year":"2012","unstructured":"Nicholas SB, Yuan J, Aminzadeh A, Norris KC, Crum A, Vaziri ND (2012) Salutary effects of a novel oxidative stress modulator on adenine-induced chronic progressive tubulointerstitial nephropathy. Am J Transl Res 4:257\u2013268","journal-title":"Am J Transl Res"},{"key":"319_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311\u2013322","journal-title":"J Cell Physiol"},{"key":"319_CR29","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/sj.ki.5001841","volume":"70","author":"PA Price","year":"2006","unstructured":"Price PA, Roublick AM, Williamson MK (2006) Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 70:1577\u20131583","journal-title":"Kidney Int"},{"key":"319_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.5935\/0101-2800.20130024","volume":"35","author":"RB Oliveira de","year":"2013","unstructured":"de Oliveira RB, Okazaki H, Stinghen AE, Drueke TB, Massy ZA, Jorgetti V (2013) Vascular calcification in chronic kidney disease: a review. Jornal brasileiro de nefrologia: \u2018orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia 35:147\u2013161","journal-title":"Jornal brasileiro de nefrologia: \u2018orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia"},{"key":"319_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.bbrc.2006.07.192","volume":"348","author":"S Smajilovic","year":"2006","unstructured":"Smajilovic S, Hansen JL, Christoffersen TE, Lewin E, Sheikh SP, Terwilliger EF, Brown EM, Haunso S, Tfelt-Hansen J (2006) Extracellular calcium sensing in rat aortic vascular smooth muscle cells. Biochem Biophys Res Commun 348:1215\u20131223","journal-title":"Biochem Biophys Res Commun"},{"key":"319_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.bbrc.2006.01.135","volume":"342","author":"RC Ziegelstein","year":"2006","unstructured":"Ziegelstein RC, Xiong Y, He C, Hu Q (2006) Expression of a functional extracellular calcium-sensing receptor in human aortic endothelial cells. Biochem Biophys Res Commun 342:153\u2013163","journal-title":"Biochem Biophys Res Commun"},{"key":"319_CR33","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2008.10.043","volume":"205","author":"O Ivanovski","year":"2009","unstructured":"Ivanovski O, Nikolov IG, Joki N, Caudrillier A, Phan O, Mentaverri R, Maizel J, Hamada Y, Nguyen-Khoa T, Fukagawa M, Kamel S, Lacour B, Drueke TB, Massy ZA (2009) The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE\u2212\/\u2212) mice. Atherosclerosis 205:55\u201362","journal-title":"Atherosclerosis"},{"key":"319_CR34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00223-010-9442-4","volume":"88","author":"FJ Mendoza","year":"2011","unstructured":"Mendoza FJ, Martinez-Moreno J, Almaden Y, Rodriguez-Ortiz ME, Lopez I, Estepa JC, Henley C, Rodriguez M, Aguilera-Tejero E (2011) Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells. Calcif Tissue Int 88:169\u2013178","journal-title":"Calcif Tissue Int"},{"key":"319_CR35","first-page":"621687","volume":"2010","author":"JR Wu-Wong","year":"2010","unstructured":"Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT (2010) Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol 2010:621687","journal-title":"Int J Endocrinol"},{"key":"319_CR36","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ki.2012.338","volume":"82","author":"H Komaba","year":"2012","unstructured":"Komaba H, Fukagawa M (2012) Vitamin D and secreted Klotho: a long-awaited panacea for vascular calcification? Kidney Int 82:1248\u20131250","journal-title":"Kidney Int"},{"key":"319_CR37","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Group MS, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (MMKD) study. J Am Soc Nephrol 18:2600\u20132608","journal-title":"J Am Soc Nephrol"},{"key":"319_CR38","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","volume":"24","author":"G Jean","year":"2009","unstructured":"Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792\u20132796","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR39","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2215\/CJN.02160212","volume":"7","author":"AM Khan","year":"2012","unstructured":"Khan AM, Chirinos JA, Litt H, Yang W, Rosas SE (2012) FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol 7:2017\u20132022","journal-title":"Clin J Am Soc Nephrol"},{"key":"319_CR40","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/ki.2009.466","volume":"77","author":"H Komaba","year":"2010","unstructured":"Komaba H, Fukagawa M (2010) FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney Int 77:292\u2013298","journal-title":"Kidney Int"},{"key":"319_CR41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584\u2013592","journal-title":"N Engl J Med"},{"key":"319_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1681\/ASN.2013050465","volume":"25","author":"JJ Scialla","year":"2014","unstructured":"Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, Zhang X, Nessel L, Hamano T, Grunwald JE, Raj DS, Yang W, He J, Lash JP, Go AS, Kusek JW, Feldman H, Wolf M, Chronic Renal Insufficiency Cohort Study I (2014) Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 25:349\u2013360","journal-title":"J Am Soc Nephrol"},{"key":"319_CR43","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Investig 121:4393\u20134408","journal-title":"J Clin Investig"},{"key":"319_CR44","first-page":"E863","volume":"304","author":"CD Touchberry","year":"2013","unstructured":"Touchberry CD, Green TM, Tchikrizov V, Mannix JE, Mao TF, Carney BW, Girgis M, Vincent RJ, Wetmore LA, Dawn B, Bonewald LF, Stubbs JR, Wacker MJ (2013) FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. American journal of physiology. Endocrinol Metab 304:E863\u2013E873","journal-title":"Endocrinol Metab"},{"key":"319_CR45","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1093\/ndt\/gft417","volume":"29","author":"KJ Martin","year":"2014","unstructured":"Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, Peacock M (2014) Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant 29:385\u2013392","journal-title":"Nephrol Dial Transplant"},{"key":"319_CR46","doi-asserted-by":"publisher","first-page":"F882","DOI":"10.1152\/ajprenal.00360.2010","volume":"299","author":"V Lavi-Moshayoff","year":"2010","unstructured":"Lavi-Moshayoff V, Wasserman G, Meir T, Silver J, Naveh-Many T (2010) PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299:F882\u2013F889","journal-title":"Am J Physiol Renal Physiol"},{"key":"319_CR47","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1681\/ASN.2011101006","volume":"23","author":"ME Rodriguez-Ortiz","year":"2012","unstructured":"Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR, Martinez-Moreno JM, Ramirez AP, Pineda C, Canalejo A, Jaeger P, Aguilera-Tejero E, Rodriguez M, Felsenfeld A, Almaden Y (2012) Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23:1190\u20131197","journal-title":"J Am Soc Nephrol"},{"key":"319_CR48","doi-asserted-by":"publisher","first-page":"E310","DOI":"10.1152\/ajpendo.00460.2012","volume":"304","author":"SJ Quinn","year":"2013","unstructured":"Quinn SJ, Thomsen AR, Pang JL, Kantham L, Brauner-Osborne H, Pollak M, Goltzman D, Brown EM (2013) Interactions between calcium and phosphorus in the regulation of the production of fibroblast growth factor 23 in vivo. Am J Physiol Endocrinol Metab 304:E310\u2013E320","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"319_CR49","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1172\/JCI61405","volume":"122","author":"V Shalhoub","year":"2012","unstructured":"Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG (2012) FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Investig 122:2543\u20132553","journal-title":"J Clin Investig"},{"key":"319_CR50","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1681\/ASN.2005111185","volume":"17","author":"S Liu","year":"2006","unstructured":"Liu S, Tang W, Zhou J, Stubbs JR, Luo Q, Pi M, Quarles LD (2006) Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17:1305\u20131315","journal-title":"J Am Soc Nephrol"},{"key":"319_CR51","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1172\/JCI29463","volume":"116","author":"R Masuyama","year":"2006","unstructured":"Masuyama R, Stockmans I, Torrekens S, Van Looveren R, Maes C, Carmeliet P, Bouillon R, Carmeliet G (2006) Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J Clin Investig 116:3150\u20133159","journal-title":"J Clin Investig"},{"key":"319_CR52","doi-asserted-by":"publisher","first-page":"F748","DOI":"10.1152\/ajprenal.00220.2007","volume":"294","author":"G Piecha","year":"2008","unstructured":"Piecha G, Kokeny G, Nakagawa K, Koleganova N, Geldyyev A, Berger I, Ritz E, Schmitt CP, Gross ML (2008) Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am J Physiol Renal Physiol 294:F748\u2013F757","journal-title":"Am J Physiol Renal Physiol"},{"key":"319_CR53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/ki.2011.105","volume":"80","author":"J Oh","year":"2011","unstructured":"Oh J, Beckmann J, Bloch J, Hettgen V, Mueller J, Li L, Hoemme M, Gross ML, Penzel R, Mundel P, Schaefer F, Schmitt CP (2011) Stimulation of the calcium-sensing receptor stabilizes the podocyte cytoskeleton, improves cell survival, and reduces toxin-induced glomerulosclerosis. Kidney Int 80:483\u2013492","journal-title":"Kidney Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00223-017-0319-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-017-0319-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T18:08:57Z","timestamp":1581962937000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00223-017-0319-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,16]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1007\/s00223-017-0319-7","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"value":"0171-967X","type":"print"},{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,16]]},"assertion":[{"value":"15 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Amgen Inc. LY, STA, KMH, CYH, DD, MS, CD, WGR, and XL are all employees and stockholders of Amgen Inc. JET and WGG were employees and stockholders of Amgen, Inc. at the time the research was conducted.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All research protocols were approved by the Institutional Animal Care and Use Committee of Amgen Inc. Human informed consent statements are not applicable since this is an animal study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}